PDB Short entry for 2I4J HEADER TRANSCRIPTION 22-AUG-06 2I4J TITLE CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST TITLE 2 LT160 (UREIDOFIBRATE DERIVATIVE) COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN (LBD), RESIDUES 223-504; COMPND 5 SYNONYM: PPAR-GAMMA; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28 KEYWDS BUNDLE OF ALPHA-HELICES AND A SMALL FOUR-STRANDED BETA-SHEET, KEYWDS 2 TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR G.POCHETTI,F.MAZZA REVDAT 5 21-FEB-24 2I4J 1 REMARK SEQADV REVDAT 4 18-OCT-17 2I4J 1 REMARK REVDAT 3 24-FEB-09 2I4J 1 VERSN REVDAT 2 26-JUN-07 2I4J 1 JRNL REVDAT 1 17-APR-07 2I4J 0 JRNL AUTH G.POCHETTI,C.GODIO,N.MITRO,D.CARUSO,A.GALMOZZI,S.SCURATI, JRNL AUTH 2 F.LOIODICE,G.FRACCHIOLLA,P.TORTORELLA,A.LAGHEZZA, JRNL AUTH 3 A.LAVECCHIA,E.NOVELLINO,F.MAZZA,M.CRESTANI JRNL TITL INSIGHTS INTO THE MECHANISM OF PARTIAL AGONISM: CRYSTAL JRNL TITL 2 STRUCTURES OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR JRNL TITL 3 GAMMA LIGAND-BINDING DOMAIN IN THE COMPLEX WITH TWO JRNL TITL 4 ENANTIOMERIC LIGANDS JRNL REF J.BIOL.CHEM. V. 282 17314 2007 JRNL REFN ISSN 0021-9258 JRNL PMID 17403688 JRNL DOI 10.1074/JBC.M702316200 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH R.T.NOLTE,G.B.WISELY,S.WESTIN,J.E.COBB,M.H.LAMBERT, REMARK 1 AUTH 2 R.KUROKAWA,M.G.ROSENFELD,T.M.WILLSON,C.K.GLASS,M.V.MILBURN REMARK 1 TITL LIGAND BINDING AND CO-ACTIVATOR ASSEMBLY OF THE PEROXISOME REMARK 1 TITL 2 PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA REMARK 1 REF NATURE V. 395 137 1998 REMARK 1 REFN ISSN 0028-0836 REMARK 1 PMID 9744270 REMARK 1 DOI 10.1038/25931 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.L.OBERFIELD,J.L.COLLINS,C.P.HOLMES,D.M.GOREHAM,J.P.COOPER, REMARK 1 AUTH 2 J.E.COBB,J.M.LENHARD,E.A.HULL-RYDE,C.P.MOHR,S.G.BLANCHARD, REMARK 1 AUTH 3 D.J.PARKS,L.B.MOORE,J.M.LEHMANN,K.PLUNKET,A.B.MILLER, REMARK 1 AUTH 4 M.V.MILBURN,S.A.KLIEWER,T.M.WILLSON REMARK 1 TITL A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND REMARK 1 TITL 2 INHIBITS ADIPOCYTE DIFFERENTIATION REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 96 6102 1999 REMARK 1 REFN ISSN 0027-8424 REMARK 1 PMID 10339548 REMARK 1 DOI 10.1073/PNAS.96.11.6102 REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 85.1 REMARK 3 NUMBER OF REFLECTIONS : 31596 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.247 REMARK 3 FREE R VALUE : 0.278 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.200 REMARK 3 FREE R VALUE TEST SET COUNT : 1569 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4332 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 33 REMARK 3 SOLVENT ATOMS : 187 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 47.34 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 3.53100 REMARK 3 B22 (A**2) : -14.52800 REMARK 3 B33 (A**2) : 10.99800 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -1.91200 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.335 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.435 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.308 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.179 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.207 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : 92.35 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : DNA-RNA_REP.PARAM REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : LT160.PAR REMARK 3 PARAMETER FILE 6 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : DNA-RNA.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : LT160.TOP REMARK 3 TOPOLOGY FILE 6 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2I4J COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 25-AUG-06. REMARK 100 THE DEPOSITION ID IS D_1000039127. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 24-MAR-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ELETTRA REMARK 200 BEAMLINE : 5.2R REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.2 REMARK 200 MONOCHROMATOR : DOUBLE CRYSTAL MONOCHROMATOR (SI REMARK 200 111 AND SI220) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALA, SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 32657 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 85.9 REMARK 200 DATA REDUNDANCY : 5.000 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04000 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.17 REMARK 200 COMPLETENESS FOR SHELL (%) : 77.8 REMARK 200 DATA REDUNDANCY IN SHELL : 5.00 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.38500 REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.93 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.51 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.8 M NACITRATE, 0.15 M TRIS, PH 8.0, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.57100 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.47350 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.57100 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.47350 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 191 REMARK 465 SER A 192 REMARK 465 HIS A 193 REMARK 465 MET A 194 REMARK 465 ALA A 195 REMARK 465 GLU A 196 REMARK 465 ILE A 197 REMARK 465 SER A 198 REMARK 465 SER A 199 REMARK 465 ASP A 200 REMARK 465 ILE A 201 REMARK 465 ASP A 202 REMARK 465 GLN A 203 REMARK 465 LEU A 204 REMARK 465 ASN A 205 REMARK 465 PRO A 206 REMARK 465 GLY B 191 REMARK 465 SER B 192 REMARK 465 HIS B 193 REMARK 465 MET B 194 REMARK 465 ALA B 195 REMARK 465 GLU B 196 REMARK 465 ILE B 197 REMARK 465 SER B 198 REMARK 465 SER B 199 REMARK 465 ASP B 200 REMARK 465 ILE B 201 REMARK 465 ASP B 202 REMARK 465 GLN B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 475 REMARK 475 ZERO OCCUPANCY RESIDUES REMARK 475 THE FOLLOWING RESIDUES WERE MODELED WITH ZERO OCCUPANCY. REMARK 475 THE LOCATION AND PROPERTIES OF THESE RESIDUES MAY NOT REMARK 475 BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 475 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE) REMARK 475 M RES C SSEQI REMARK 475 ASP A 260 REMARK 475 PHE A 264 REMARK 475 HIS A 266 REMARK 475 LEU A 270 REMARK 475 GLN A 271 REMARK 475 GLU A 272 REMARK 475 GLN A 273 REMARK 475 SER A 274 REMARK 475 LYS B 261 REMARK 475 LYS B 265 REMARK 475 HIS B 266 REMARK 475 THR B 268 REMARK 475 GLN B 271 REMARK 475 GLU B 272 REMARK 475 GLN B 273 REMARK 475 SER B 274 REMARK 475 GLU B 276 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 ILE A 267 N CA C O CB CG1 CG2 REMARK 480 ASP B 260 CA C O CB CG OD1 OD2 REMARK 480 ILE B 262 CB CG1 CG2 REMARK 480 LYS B 263 CB CG CD CE NZ REMARK 480 PHE B 264 CB CG CD1 CD2 CE1 CE2 CZ REMARK 480 ILE B 267 N CA C O CB CG1 CG2 REMARK 480 LEU B 476 OXT REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 244 55.43 -142.40 REMARK 500 GLU A 259 21.40 -77.11 REMARK 500 ASP A 260 -66.46 -109.33 REMARK 500 PRO A 269 -144.30 -61.22 REMARK 500 GLU A 272 -85.70 -40.55 REMARK 500 LYS A 275 84.75 49.91 REMARK 500 GLU A 276 163.39 -46.57 REMARK 500 SER A 342 75.28 39.35 REMARK 500 GLU A 343 17.57 55.48 REMARK 500 ARG A 357 145.25 -37.39 REMARK 500 LYS A 358 -67.12 -14.10 REMARK 500 LYS A 474 21.43 -153.38 REMARK 500 ASP A 475 -2.66 65.66 REMARK 500 LEU B 237 -153.49 -60.57 REMARK 500 THR B 238 99.75 -32.68 REMARK 500 LYS B 240 -82.36 -105.29 REMARK 500 THR B 242 103.85 -42.01 REMARK 500 ASP B 243 136.26 164.10 REMARK 500 HIS B 266 -78.04 -168.60 REMARK 500 GLU B 272 81.53 -170.09 REMARK 500 LYS B 275 91.46 52.27 REMARK 500 ARG B 357 155.61 -35.83 REMARK 500 SER B 394 -122.60 -64.81 REMARK 500 HIS B 425 53.41 -144.54 REMARK 500 LYS B 458 36.52 -86.51 REMARK 500 THR B 459 -70.31 -135.43 REMARK 500 THR B 461 -87.49 -154.35 REMARK 500 ASP B 462 -177.97 -37.87 REMARK 500 MET B 463 127.59 85.42 REMARK 500 HIS B 466 -12.99 103.88 REMARK 500 PRO B 467 175.36 -58.87 REMARK 500 LEU B 468 -32.06 70.87 REMARK 500 LYS B 474 -97.49 60.50 REMARK 500 ASP B 475 -25.90 -149.05 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE DRJ A 999 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PRG RELATED DB: PDB REMARK 900 LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATIOR REMARK 900 ACTIVATED RECEPTOR GAMMA, APOFORM REMARK 900 RELATED ID: 2PRG RELATED DB: PDB REMARK 900 THE TERNARY COMPLEX OF THE SAME PROTEIN WITH ROSIGLITAZONE AND THE REMARK 900 COACTIVATOR PEPTIDE SRC-1 REMARK 900 RELATED ID: 4PRG RELATED DB: PDB REMARK 900 THE SAME PROTEIN COMPLEXED WITH THE PARTIAL AGONIST GW0072 REMARK 900 RELATED ID: 2I4Z RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL REMARK 900 AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN REMARK 900 OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS DBREF 2I4J A 195 476 UNP P37231 PPARG_HUMAN 223 504 DBREF 2I4J B 195 476 UNP P37231 PPARG_HUMAN 223 504 SEQADV 2I4J GLY A 191 UNP P37231 EXPRESSION TAG SEQADV 2I4J SER A 192 UNP P37231 EXPRESSION TAG SEQADV 2I4J HIS A 193 UNP P37231 EXPRESSION TAG SEQADV 2I4J MET A 194 UNP P37231 EXPRESSION TAG SEQADV 2I4J GLY B 191 UNP P37231 EXPRESSION TAG SEQADV 2I4J SER B 192 UNP P37231 EXPRESSION TAG SEQADV 2I4J HIS B 193 UNP P37231 EXPRESSION TAG SEQADV 2I4J MET B 194 UNP P37231 EXPRESSION TAG SEQRES 1 A 286 GLY SER HIS MET ALA GLU ILE SER SER ASP ILE ASP GLN SEQRES 2 A 286 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 3 A 286 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 4 A 286 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 5 A 286 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 6 A 286 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 7 A 286 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 8 A 286 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 9 A 286 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 10 A 286 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 11 A 286 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 12 A 286 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 13 A 286 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 14 A 286 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 15 A 286 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 16 A 286 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 17 A 286 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 18 A 286 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 19 A 286 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 20 A 286 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 21 A 286 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 22 A 286 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU SEQRES 1 B 286 GLY SER HIS MET ALA GLU ILE SER SER ASP ILE ASP GLN SEQRES 2 B 286 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 3 B 286 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 4 B 286 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 5 B 286 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 6 B 286 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 7 B 286 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 8 B 286 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 9 B 286 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 10 B 286 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 11 B 286 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 12 B 286 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 13 B 286 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 14 B 286 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 15 B 286 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 16 B 286 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 17 B 286 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 18 B 286 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 19 B 286 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 20 B 286 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 21 B 286 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 22 B 286 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU HET DRJ A 999 33 HETNAM DRJ (2R)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL) HETNAM 2 DRJ AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID FORMUL 3 DRJ C27 H36 N2 O4 FORMUL 4 HOH *187(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 ILE A 262 1 12 HELIX 4 4 GLU A 276 ILE A 303 1 28 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 ALA A 331 1 22 HELIX 7 7 SER A 342 GLY A 344 5 3 HELIX 8 8 ARG A 350 SER A 355 1 6 HELIX 9 9 PRO A 359 PHE A 363 5 5 HELIX 10 10 MET A 364 ALA A 376 1 13 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 GLN A 430 GLU A 460 1 31 HELIX 14 14 HIS A 466 TYR A 473 1 8 HELIX 15 15 GLU B 207 PHE B 226 1 20 HELIX 16 16 THR B 229 LEU B 237 1 9 HELIX 17 17 ASP B 251 ASP B 260 1 10 HELIX 18 18 GLU B 276 SER B 302 1 27 HELIX 19 19 ASP B 310 LEU B 333 1 24 HELIX 20 20 ARG B 350 SER B 355 1 6 HELIX 21 21 ARG B 357 ASP B 362 1 6 HELIX 22 22 MET B 364 ALA B 376 1 13 HELIX 23 23 ASP B 380 LEU B 393 1 14 HELIX 24 24 ASN B 402 HIS B 425 1 24 HELIX 25 25 GLN B 430 LYS B 458 1 29 HELIX 26 26 LEU B 468 LYS B 474 1 7 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O THR A 349 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N ILE B 341 O GLY B 346 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 SITE 1 AC1 19 PHE A 226 CYS A 285 GLN A 286 ARG A 288 SITE 2 AC1 19 SER A 289 ALA A 292 ILE A 296 HIS A 323 SITE 3 AC1 19 ILE A 326 MET A 329 VAL A 339 LEU A 340 SITE 4 AC1 19 ILE A 341 HIS A 449 LEU A 453 LEU A 465 SITE 5 AC1 19 LEU A 469 TYR A 473 HOH A1104 CRYST1 93.142 60.947 118.106 90.00 103.26 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010736 0.000000 0.002530 0.00000 SCALE2 0.000000 0.016408 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008699 0.00000